| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1038/NRD.2015.37 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/nrd.2015.37 |
| P932 | PMC publication ID | 7097181 |
| P698 | PubMed publication ID | 26868298 |
| P5875 | ResearchGate publication ID | 294257406 |
| P50 | author | Yuen Kwok-yung | Q8060280 |
| Alimuddin Zumla | Q4726678 | ||
| Esam I Azhar | Q56807752 | ||
| Jasper Fuk-Woo Chan | Q28754326 | ||
| David Shu-cheong Hui | Q40358502 | ||
| P2860 | cites work | Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus | Q57769050 |
| Severe Acute Respiratory Syndrome | Q59314305 | ||
| Development of interfering RNA agents to inhibit SARS-associated coronavirus infection and replication | Q63561195 | ||
| [Analysis on the characteristics of blood serum Ab-IgG detective result of severe acute respiratory syndrome patients in Guangzhou, China] | Q64132415 | ||
| Treatment of SARS with human interferons | Q73738906 | ||
| Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor | Q82697155 | ||
| Middle East Respiratory Syndrome | Q85487309 | ||
| Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation | Q99204138 | ||
| A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion | Q21089597 | ||
| State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans | Q21128649 | ||
| Infection with MERS-CoV causes lethal pneumonia in the common marmoset | Q21131359 | ||
| Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus | Q21131361 | ||
| Broad-spectrum antiviral therapeutics | Q21135293 | ||
| A systematic screen of FDA-approved drugs for inhibitors of biological threat agents | Q21559667 | ||
| Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC | Q24329089 | ||
| Human aminopeptidase N is a receptor for human coronavirus 229E | Q24338168 | ||
| Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats | Q24536078 | ||
| Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay | Q24567771 | ||
| Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines | Q24600523 | ||
| Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group | Q24604486 | ||
| Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models | Q24610025 | ||
| Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses | Q24617467 | ||
| Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae | Q24648487 | ||
| Comparative analysis of twelve genomes of three novel group 2c and group 2d coronaviruses reveals unique group and subgroup features | Q24675714 | ||
| Chloroquine is a potent inhibitor of SARS coronavirus infection and spread | Q24815979 | ||
| Design of wide-spectrum inhibitors targeting coronavirus main proteases | Q24817106 | ||
| Suppression of coronavirus replication by cyclophilin inhibitors | Q26825245 | ||
| Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deISGylating activities | Q26825953 | ||
| Development of a transgenic mouse model susceptible to human coronavirus 229E. | Q33836457 | ||
| Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry | Q33841118 | ||
| Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human | Q33849474 | ||
| Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques | Q33887877 | ||
| Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry | Q33920306 | ||
| Effects of chloroquine on viral infections: an old drug against today's diseases? | Q33973620 | ||
| Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures | Q33981191 | ||
| The management of coronavirus infections with particular reference to SARS. | Q34012358 | ||
| Singlet oxygen effects on lipid membranes: implications for the mechanism of action of broad-spectrum viral fusion inhibitors | Q34039661 | ||
| Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. | Q34040052 | ||
| Detection of Middle East respiratory syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP). | Q34042661 | ||
| Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses | Q34058240 | ||
| Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture | Q34058365 | ||
| Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design | Q34059855 | ||
| The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors | Q34064211 | ||
| Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever | Q34148663 | ||
| Culturing the unculturable: human coronavirus HKU1 infects, replicates, and produces progeny virions in human ciliated airway epithelial cell cultures | Q34190552 | ||
| Aetiology: Koch's postulates fulfilled for SARS virus | Q34197103 | ||
| Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat | Q34261861 | ||
| Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction | Q34304123 | ||
| Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase | Q34316979 | ||
| Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. | Q34317027 | ||
| Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design | Q34324907 | ||
| Resistance to enfuvirtide, the first HIV fusion inhibitor | Q34330766 | ||
| Antiviral drugs specific for coronaviruses in preclinical development | Q34332580 | ||
| Family cluster of Middle East respiratory syndrome coronavirus infections | Q34347450 | ||
| Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts | Q34396455 | ||
| Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein | Q34408840 | ||
| Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen | Q34442119 | ||
| Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis | Q34452682 | ||
| Protease inhibitors targeting coronavirus and filovirus entry | Q34461982 | ||
| Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease | Q34468689 | ||
| Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality | Q34560099 | ||
| Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests | Q34650448 | ||
| MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment | Q34650943 | ||
| The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies | Q34653419 | ||
| High-frequency ultrasound imaging of the duodenum and colon in patients with symptomatic giardiasis in comparison to amebiasis and healthy subjects | Q34655022 | ||
| Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. | Q34656339 | ||
| Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo | Q34666875 | ||
| Interspecies transmission and emergence of novel viruses: lessons from bats and birds | Q34774311 | ||
| From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design | Q26992345 | ||
| The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis | Q27001157 | ||
| Current advancements and potential strategies in the development of MERS-CoV vaccines | Q27012578 | ||
| Middle East respiratory syndrome: obstacles and prospects for vaccine development | Q27013314 | ||
| Nitazoxanide: a first-in-class broad-spectrum antiviral agent | Q27021914 | ||
| SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum | Q27332392 | ||
| A broad-spectrum antiviral targeting entry of enveloped viruses | Q27491286 | ||
| In Vitro and In Vivo Studies of the Trypanocidal Properties of WRR-483 against Trypanosoma cruzi | Q27664609 | ||
| Structure of the Fusion Core and Inhibition of Fusion by a Heptad Repeat Peptide Derived from the S Protein of Middle East Respiratory Syndrome Coronavirus | Q27680061 | ||
| Structural Basis for the Identification of the N-Terminal Domain of Coronavirus Nucleocapsid Protein as an Antiviral Target | Q27681874 | ||
| X-ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like Proteases | Q27681891 | ||
| Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor | Q27689029 | ||
| Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26 | Q27695604 | ||
| Middle East respiratory syndrome coronavirus (MERS-CoV): animal to human interaction | Q28073640 | ||
| Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus | Q28188496 | ||
| Coronavirus as a possible cause of severe acute respiratory syndrome | Q28200848 | ||
| Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis | Q28235257 | ||
| Bats are natural reservoirs of SARS-like coronaviruses | Q28274751 | ||
| Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection | Q28383088 | ||
| Structure and inhibition of the SARS coronavirus envelope protein ion channel | Q28475712 | ||
| Cure of hookworm infection with a cysteine protease inhibitor | Q28480978 | ||
| Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility | Q28660530 | ||
| Identification of a novel coronavirus in patients with severe acute respiratory syndrome | Q29615907 | ||
| A novel coronavirus associated with severe acute respiratory syndrome | Q29617553 | ||
| Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia | Q29618053 | ||
| Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China | Q29618055 | ||
| Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry | Q29620710 | ||
| Rapid generation of a mouse model for Middle East respiratory syndrome | Q30217177 | ||
| Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor | Q30219701 | ||
| Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? | Q30223960 | ||
| Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S. | Q30230264 | ||
| Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir | Q30317509 | ||
| Human coronavirus HKU1 infection of primary human type II alveolar epithelial cells: cytopathic effects and innate immune response. | Q34875544 | ||
| Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus | Q35008480 | ||
| Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation | Q35009468 | ||
| A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines | Q35063993 | ||
| Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? | Q35097505 | ||
| Discovery of a novel coronavirus, China Rattus coronavirus HKU24, from Norway rats supports the murine origin of Betacoronavirus 1 and has implications for the ancestor of Betacoronavirus lineage A | Q35110987 | ||
| Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells | Q35123537 | ||
| Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein | Q35159147 | ||
| Development and validation of a rapid immunochromatographic assay for detection of Middle East respiratory syndrome coronavirus antigen in dromedary camels | Q35193329 | ||
| Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic | Q35214004 | ||
| Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease | Q35487986 | ||
| Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. | Q35536588 | ||
| Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor | Q35635252 | ||
| Acute middle East respiratory syndrome coronavirus infection in livestock Dromedaries, Dubai, 2014. | Q35673405 | ||
| SARS--beginning to understand a new virus | Q35701656 | ||
| Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity | Q35739055 | ||
| Human Coronavirus HKU1 Spike Protein Uses O-Acetylated Sialic Acid as an Attachment Receptor Determinant and Employs Hemagglutinin-Esterase Protein as a Receptor-Destroying Enzyme | Q35758573 | ||
| Effects of singlet oxygen generated by a broad-spectrum viral fusion inhibitor on membrane nanoarchitecture | Q35768114 | ||
| Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection | Q35865538 | ||
| Development and Evaluation of Novel Real-Time Reverse Transcription-PCR Assays with Locked Nucleic Acid Probes Targeting Leader Sequences of Human-Pathogenic Coronaviruses | Q35868692 | ||
| Viral loads in clinical specimens and SARS manifestations. | Q35872810 | ||
| Epidemiologic clues to SARS origin in China | Q35880454 | ||
| Antibodies to SARS coronavirus in civets | Q35881133 | ||
| Medical treatment of viral pneumonia including SARS in immunocompetent adult | Q35913357 | ||
| The Nucleocapsid Protein of Coronaviruses Acts as a Viral Suppressor of RNA Silencing in Mammalian Cells | Q35913883 | ||
| Evaluation of candidate vaccine approaches for MERS-CoV. | Q35917397 | ||
| Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus | Q35989939 | ||
| SARS-CoV infection in a restaurant from palm civet | Q36009490 | ||
| A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus | Q36073689 | ||
| Comparison of SARS and NL63 papain-like protease binding sites and binding site dynamics: inhibitor design implications | Q36095703 | ||
| Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection | Q36306931 | ||
| Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans | Q36432023 | ||
| Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV | Q36496355 | ||
| Cross-species transmission and emergence of novel viruses from birds | Q37842058 | ||
| A cluster of cases of severe acute respiratory syndrome in Hong Kong. | Q37869740 | ||
| Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential | Q37929687 | ||
| The emerging novel Middle East respiratory syndrome coronavirus: the "knowns" and "unknowns". | Q38123917 | ||
| Clinical management and infection control of SARS: lessons learned | Q38133142 | ||
| Severe acute respiratory syndrome vs. the Middle East respiratory syndrome | Q38195726 | ||
| MERS-CoV papain-like protease has deISGylating and deubiquitinating activities | Q38315802 | ||
| A systematic approach to novel virus discovery in emerging infectious disease outbreaks. | Q38369217 | ||
| Seroconversion to HCoV-NL63 in Rhesus Macaques | Q38613530 | ||
| ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells | Q38912734 | ||
| Tropism and replication of Middle East respiratory syndrome coronavirus from dromedary camels in the human respiratory tract: an in-vitro and ex-vivo study. | Q38937919 | ||
| Assessment of the Middle East respiratory syndrome coronavirus (MERS-CoV) epidemic in the Middle East and risk of international spread using a novel maximum likelihood analysis approach | Q39171246 | ||
| TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium | Q39174513 | ||
| Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation | Q39175230 | ||
| Application of siRNA against SARS in the rhesus macaque model | Q39321848 | ||
| Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. | Q39349816 | ||
| Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque | Q39362979 | ||
| Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. | Q39410431 | ||
| 2,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both hepatitis C virus (HCV) and SARS-associated coronavirus (SCV). | Q39472319 | ||
| Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus | Q39635009 | ||
| Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy | Q39727842 | ||
| Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus | Q39855747 | ||
| Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors | Q40030137 | ||
| Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. | Q40041391 | ||
| IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study | Q40159258 | ||
| Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia | Q40187493 | ||
| Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia | Q40200316 | ||
| Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial | Q40206357 | ||
| Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients | Q40210753 | ||
| Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication | Q40260580 | ||
| Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus | Q40416852 | ||
| In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. | Q40492029 | ||
| Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients | Q40523218 | ||
| Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study | Q40543264 | ||
| Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. | Q40544493 | ||
| Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein | Q40548165 | ||
| Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China | Q40554400 | ||
| Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study | Q40557821 | ||
| Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. | Q40559650 | ||
| Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference | Q40585048 | ||
| The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity | Q40670135 | ||
| Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice | Q40744757 | ||
| Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults | Q40836022 | ||
| Spread of MERS to South Korea and China | Q40862258 | ||
| An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels | Q40867301 | ||
| Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study | Q41088356 | ||
| Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways | Q41094209 | ||
| Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. | Q30351904 | ||
| Infectious diseases emerging from Chinese wet-markets: zoonotic origins of severe respiratory viral infections. | Q30356546 | ||
| Tmprss2 is essential for influenza H1N1 virus pathogenesis in mice. | Q30356975 | ||
| Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. | Q30359335 | ||
| A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant | Q30360627 | ||
| Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. | Q30362113 | ||
| Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses. | Q30362760 | ||
| Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. | Q30368736 | ||
| The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. | Q30370367 | ||
| Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. | Q30371303 | ||
| A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. | Q30379384 | ||
| Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. | Q30398715 | ||
| Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection | Q30419612 | ||
| Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. | Q30427729 | ||
| Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin | Q30429521 | ||
| Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development | Q30432706 | ||
| Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice | Q30833219 | ||
| Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine | Q33230687 | ||
| A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice | Q33269158 | ||
| A major outbreak of severe acute respiratory syndrome in Hong Kong | Q33347382 | ||
| A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication | Q33375590 | ||
| A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma | Q33390586 | ||
| Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study | Q33409373 | ||
| Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection | Q33413007 | ||
| mRNA display design of fibronectin-based intrabodies that detect and inhibit severe acute respiratory syndrome coronavirus nucleocapsid protein | Q33429766 | ||
| Coronavirus diversity, phylogeny and interspecies jumping | Q33471964 | ||
| Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses | Q33506083 | ||
| Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses | Q33583009 | ||
| Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution | Q33627189 | ||
| Hospital outbreak of Middle East respiratory syndrome coronavirus | Q33642332 | ||
| Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease | Q33695621 | ||
| Identification of diverse alphacoronaviruses and genomic characterization of a novel severe acute respiratory syndrome-like coronavirus from bats in China | Q33743774 | ||
| A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. | Q33743790 | ||
| Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses | Q33756740 | ||
| ??? | Q24596042 | ||
| Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus | Q36691163 | ||
| A review of studies on animal reservoirs of the SARS coronavirus | Q36798770 | ||
| Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description | Q36807417 | ||
| Isolation and characterization of current human coronavirus strains in primary human epithelial cell cultures reveal differences in target cell tropism | Q36827218 | ||
| The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies | Q36827306 | ||
| Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV | Q36835873 | ||
| Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus | Q36872701 | ||
| Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures | Q36911737 | ||
| Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein | Q36911828 | ||
| The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists | Q36922964 | ||
| The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease | Q36923117 | ||
| Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein | Q36972346 | ||
| The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters | Q36976427 | ||
| Pancreatic stellate cells: new target in the treatment of chronic pancreatitis | Q36998028 | ||
| A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV | Q37152873 | ||
| Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate | Q37174550 | ||
| TMPRSS2 is an activating protease for respiratory parainfluenza viruses. | Q37252750 | ||
| Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors | Q37252823 | ||
| Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist | Q37254398 | ||
| Pneumonia from human coronavirus in a macaque model | Q37273712 | ||
| A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection | Q37335883 | ||
| Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. | Q37336487 | ||
| Reverse transcription recombinase polymerase amplification assay for the detection of middle East respiratory syndrome coronavirus | Q37410980 | ||
| In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East Respiratory Syndrome (MERS) Coronavirus infection | Q37425357 | ||
| Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study | Q37504790 | ||
| Replicative Capacity of MERS Coronavirus in Livestock Cell Lines | Q37513472 | ||
| Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus | Q37565476 | ||
| Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays | Q37593209 | ||
| Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors | Q37596746 | ||
| Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets | Q37596935 | ||
| Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus | Q37621643 | ||
| Isolation, propagation, genome analysis and epidemiology of HKU1 betacoronaviruses | Q37680642 | ||
| Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response. | Q37713995 | ||
| Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset | Q41096904 | ||
| Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein | Q41199088 | ||
| Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus | Q41242033 | ||
| A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters | Q41338114 | ||
| 2014 MERS-CoV outbreak in Jeddah--a link to health care facilities | Q41351922 | ||
| MERS CoV infection in two renal transplant recipients: case report | Q41463582 | ||
| Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. | Q41718118 | ||
| Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice | Q41752133 | ||
| Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus | Q41908949 | ||
| In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine | Q41913526 | ||
| Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody | Q41920484 | ||
| Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice | Q41943954 | ||
| Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. | Q42020947 | ||
| Transmission of MERS-coronavirus in household contacts | Q42197387 | ||
| Evidence for camel-to-human transmission of MERS coronavirus | Q42212312 | ||
| Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases | Q42218522 | ||
| Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. | Q42219678 | ||
| Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation | Q42236132 | ||
| Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study | Q42244203 | ||
| Taking stock of the first 133 MERS coronavirus cases globally--Is the epidemic changing? | Q42245526 | ||
| Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis | Q42246665 | ||
| Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies | Q42249511 | ||
| Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. | Q42251659 | ||
| Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation | Q42253657 | ||
| An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus | Q42256274 | ||
| Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. | Q42269949 | ||
| Index patient and SARS outbreak in Hong Kong | Q42551827 | ||
| Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease | Q42614265 | ||
| Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry | Q42786664 | ||
| Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. | Q43048687 | ||
| Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease | Q43252092 | ||
| Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids | Q43530903 | ||
| Development of a standard treatment protocol for severe acute respiratory syndrome | Q44441633 | ||
| Fatal aspergillosis in a patient with SARS who was treated with corticosteroids | Q44532562 | ||
| Attenuation of SARS coronavirus by a short hairpin RNA expression plasmid targeting RNA-dependent RNA polymerase | Q44653963 | ||
| Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. | Q44950223 | ||
| Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor | Q45113065 | ||
| Inhibition of SARS-CoV replication by siRNA. | Q45206542 | ||
| A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses | Q45423400 | ||
| Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets | Q45501850 | ||
| The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. | Q46409785 | ||
| Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors | Q46427243 | ||
| Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys | Q47812425 | ||
| Use of convalescent plasma therapy in SARS patients in Hong Kong | Q47875099 | ||
| Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. | Q47925901 | ||
| Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques | Q48015946 | ||
| Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice. | Q48623426 | ||
| Middle East respiratory syndrome. | Q51011540 | ||
| Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. | Q51660929 | ||
| Advancing priority research on the Middle East respiratory syndrome coronavirus. | Q51859624 | ||
| Aryl diketoacids (ADK) selectively inhibit duplex DNA-unwinding activity of SARS coronavirus NTPase/helicase. | Q52592103 | ||
| Severe acute respiratory syndrome | Q56775278 | ||
| P433 | issue | 5 | |
| P921 | main subject | respiratory tract infection | Q754447 |
| drug discovery | Q1418791 | ||
| P304 | page(s) | 327-347 | |
| P577 | publication date | 2016-02-12 | |
| 2016-05-01 | |||
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Coronaviruses - drug discovery and therapeutic options | |
| P478 | volume | 15 |
| Q90550428 | 2019 novel Coronavirus outbreak: a quiz or final exam? |
| Q99240141 | A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges |
| Q95276746 | A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19) |
| Q99559831 | A dynamic simulation study of FDA drug from zinc database against COVID-19 main protease receptor |
| Q40064548 | A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective. |
| Q95651716 | A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19) |
| Q30248209 | A review of treatment modalities for Middle East Respiratory Syndrome |
| Q91800366 | A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin |
| Q99622171 | ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19 |
| Q97882663 | Advances and challenges in the prevention and treatment of COVID-19 |
| Q94520926 | An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development |
| Q47132991 | An Opportunistic Pathogen Afforded Ample Opportunities: Middle East Respiratory Syndrome Coronavirus |
| Q91610063 | An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice |
| Q64230886 | An updated roadmap for MERS-CoV research and product development: focus on diagnostics |
| Q93201918 | Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening |
| Q91944602 | Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods |
| Q98184361 | Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients |
| Q90724489 | Antipsoriatic treatments during COVID-19 outbreak |
| Q27755387 | Approved Antiviral Drugs over the Past 50 Years |
| Q97517831 | Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic? |
| Q54227950 | Bats, Coronaviruses, and Deforestation: Toward the Emergence of Novel Infectious Diseases? |
| Q97536475 | Bioengineering tools to speed up the discovery and preclinical testing of vaccines for SARS-CoV-2 and therapeutic agents for COVID-19 |
| Q95601929 | Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease |
| Q96431581 | Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease |
| Q93240693 | Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2 |
| Q89990499 | Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential |
| Q84315461 | Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase |
| Q38665457 | Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. |
| Q97518345 | COVID-19 and the Chemical Senses: Supporting Players Take Center Stage |
| Q90602641 | COVID-19 infection and rheumatoid arthritis: Faraway, so close! |
| Q90425437 | COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics |
| Q91824849 | COVID-19: A promising cure for the global panic |
| Q94487346 | COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives |
| Q94956600 | COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons |
| Q94596745 | COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus |
| Q96030752 | COVID-19: Transmission, Prevention, and Potential Therapeutic Opportunities |
| Q90814887 | COVID-19: a new challenge for human beings |
| Q90744942 | COVID-19: what has been learned and to be learned about the novel coronavirus disease |
| Q38753926 | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Is an Important Surface Attachment Factor That Facilitates Entry of Middle East Respiratory Syndrome Coronavirus |
| Q97526973 | Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options |
| Q61816159 | Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication |
| Q110453608 | Characterization of the SARS-CoV-2 E Protein: Sequence, Structure, Viroporin, and Inhibitors |
| Q95630795 | Chemistry and Biology of SARS-CoV-2 |
| Q99552268 | Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects? |
| Q56781312 | Combination Attenuation Offers Strategy for Live Attenuated Coronavirus Vaccines |
| Q23302003 | Comparative genomic analysis of pre-epidemic and epidemic Zika virus strains for virological factors potentially associated with the rapidly expanding epidemic |
| Q88486711 | Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV |
| Q90727836 | Competing endogenous RNA network profiling reveals novel host dependency factors required for MERS-CoV propagation |
| Q97551132 | Computational insights into tetracyclines as inhibitors against SARS-CoV-2 Mpro via combinatorial molecular simulation calculations |
| Q92076061 | Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children |
| Q53704198 | Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. |
| Q90322109 | Coronavirus disease 2019: What we know? |
| Q64287253 | Coronavirus envelope protein: current knowledge |
| Q97520945 | Coronaviruses and Central Nervous System Manifestations |
| Q100510827 | Crystal Structure of Non-Structural Protein 10 from Severe Acute Respiratory Syndrome Coronavirus-2 |
| Q97525097 | Current strategies against COVID-19 |
| Q94491965 | Current targeted therapeutics against COVID-19: Based on first-line experience in China |
| Q40061001 | Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review |
| Q96342930 | Cytokine Storm Induced by SARS-CoV-2 |
| Q104799886 | D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction |
| Q97644540 | Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19 |
| Q61800839 | Development and Evaluation of a Multiplexed Immunoassay for Simultaneous Detection of Serum IgG Antibodies to Six Human Coronaviruses |
| Q26700054 | Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus |
| Q60952662 | Development of Small-Molecule MERS-CoV Inhibitors |
| Q100464664 | Development of an antibody-dependent cellular cytotoxicity reporter assay for measuring anti-Middle East Respiratory Syndrome antibody bioactivity |
| Q95601719 | Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro |
| Q96027156 | Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system |
| Q93180376 | Drug Development and Medicinal Chemistry Efforts Toward SARS-Coronavirus and Covid-19 Therapeutics |
| Q97528635 | Drug targets for COVID-19 therapeutics: Ongoing global efforts |
| Q99569581 | Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19 |
| Q90156311 | Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial |
| Q99630909 | Efficacy and safety of herbal medicine (Lianhuaqingwen) for treating COVID-19: A systematic review and meta-analysis |
| Q40044232 | Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies. |
| Q30238587 | Epidemic and Emerging Coronaviruses (Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome). |
| Q97522378 | Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis |
| Q97530819 | Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CLpro targeting repurposed drug candidates |
| Q26247946 | Fighting viruses with antibiotics: an overlooked path |
| Q99593526 | Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein |
| Q84315943 | Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus |
| Q57790134 | Generation and characterization of a monoclonal antibody against MERS-CoV targeting the spike protein using a synthetic peptide epitope-CpG-DNA-liposome complex |
| Q30148692 | Global epidemiology of non-influenza RNA respiratory viruses: data gaps and a growing need for surveillance |
| Q27728036 | Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy |
| Q43167862 | Glycan shield and fusion activation of a deltacoronavirus spike glycoprotein fine-tuned for enteric infections. |
| Q54217812 | Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. |
| Q64126568 | High-throughput Screening and Identification of Potent Broad-spectrum Inhibitors of Coronaviruses |
| Q38795745 | Host-directed therapies for infectious diseases: current status, recent progress, and future prospects |
| Q42051486 | Human Coronaviruses: A Review of Virus-Host Interactions. |
| Q92800064 | Identification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling |
| Q98384563 | Identification of 4-Anilino-6-aminoquinazoline Derivatives as Potential MERS-CoV Inhibitors |
| Q100661107 | Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening |
| Q84316279 | Identification of the immunodominant neutralizing regions in the spike glycoprotein of porcine deltacoronavirus |
| Q100737230 | Immunity, endothelial injury and complement-induced coagulopathy in COVID-19 |
| Q92168725 | In silico and in vitro analysis of small molecules and natural compounds targeting the 3CL protease of feline infectious peritonitis virus |
| Q26970798 | Infectious diseases epidemic threats and mass gatherings: refocusing global attention on the continuing spread of the Middle East Respiratory syndrome coronavirus (MERS-CoV) |
| Q98633611 | Inhibition of porcine epidemic diarrhea virus (PEDV) replication by A77 1726 through targeting JAK and Src tyrosine kinases |
| Q99624086 | Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2 |
| Q44843636 | Interferon regulated gene (IRG) expression-signature in a mouse model of chikungunya virus neurovirulence |
| Q95264427 | Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19 ? |
| Q89337829 | Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) |
| Q94491933 | Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway |
| Q99237557 | Localization of Cell Receptor-Related Genes of SARS-CoV-2 in the Kidney through Single-Cell Transcriptome Analysis |
| Q93213779 | Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan |
| Q40559478 | MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2. |
| Q47738282 | MERS, SARS and other coronaviruses as causes of pneumonia. |
| Q39374922 | MERS-coronavirus: From discovery to intervention. |
| Q99631257 | Managing the COVID-19 Pandemic: Research Strategies Based on the Evolutionary and Molecular Characteristics of Coronaviruses |
| Q100490995 | Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters |
| Q61814884 | Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism |
| Q40558082 | Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus |
| Q90127018 | Middle East respiratory syndrome |
| Q40085786 | Middle East respiratory syndrome coronavirus: five years later. |
| Q54230978 | Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. |
| Q90576857 | Middle East respiratory syndrome: pathogenesis and therapeutic developments |
| Q104471885 | Minimal system for assembly of SARS-CoV-2 virus like particles |
| Q57094095 | Modeling pathogenesis of emergent and pre-emergent human coronaviruses in mice |
| Q30244813 | Molecular Basis of Coronavirus Virulence and Vaccine Development |
| Q91912232 | Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins |
| Q98771881 | Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19 |
| Q99629363 | Molecular dynamics simulation of docking structures of SARS-CoV-2 main protease and HIV protease inhibitors |
| Q87748572 | Molecular immune pathogenesis and diagnosis of COVID-19 |
| Q59354303 | NAADP-dependent Ca signaling regulates Middle East respiratory syndrome-coronavirus pseudovirus translocation through the endolysosomal system |
| Q98157481 | Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19 |
| Q84316075 | Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells |
| Q90482543 | Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 |
| Q96647455 | New Insights of Emerging SARS-CoV-2: Epidemiology, Etiology, Clinical Features, Clinical Treatment, and Prevention |
| Q91912173 | Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels |
| Q94491938 | Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management |
| Q92047931 | Novel Guanosine Derivatives against MERS CoV polymerase: An in silico perspective |
| Q84315443 | Nucleoside analogues for the treatment of coronavirus infections |
| Q52644426 | Nucleosides for the treatment of respiratory RNA virus infections. |
| Q88977789 | Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase |
| Q82839925 | Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle |
| Q66679577 | Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections |
| Q96348573 | Overview of lethal human coronaviruses |
| Q39279748 | Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology |
| Q98571334 | Pharmacological treatments of COVID-19 |
| Q97517081 | Pharmacotherapics Advice in Guidelines for COVID-19 |
| Q93237085 | Pharmacotherapy in COVID-19; A narrative review for emergency providers |
| Q107981570 | Piece of the puzzle: Remdesivir disassembles the multimeric SARS-CoV-2 RNA-dependent RNA polymerase complex |
| Q98771815 | Plants Metabolites: Possibility of Natural Therapeutics Against the COVID-19 Pandemic |
| Q95321983 | Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19 |
| Q96342888 | Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China |
| Q96124554 | Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements |
| Q99575411 | Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach |
| Q98290383 | Principles and treatment strategies for the use of Chinese herbal medicine in patients at different stages of coronavirus infection |
| Q93263973 | Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study |
| Q36198462 | Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses |
| Q98465610 | Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis |
| Q90255727 | Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds |
| Q93154073 | Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status |
| Q89606283 | Reducing mortality from 2019-nCoV: host-directed therapies should be an option |
| Q84360011 | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro |
| Q94674303 | Research Progress of Drug Treatment in Novel Coronavirus Pneumonia |
| Q95610020 | Reversal of Infected Host Gene Expression Identifies Repurposed Drug Candidates for COVID-19 |
| Q104134910 | Reverse C-glycosidase reaction provides C-nucleotide building blocks of xenobiotic nucleic acids |
| Q106996867 | Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19 |
| Q97430314 | Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review |
| Q96342886 | Role of the GTNGTKR motif in the N-terminal receptor-binding domain of the SARS-CoV-2 spike protein |
| Q99545069 | SAR of novel benzamides and isoindolines, designed as SARS-CoV protease inhibitors - effective against SARS-CoV-2 |
| Q107210867 | SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target |
| Q99240705 | SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies |
| Q93218625 | SARS-Cov-2 (human) and COVID-19: Primer 2020 |
| Q60912768 | SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target |
| Q54978341 | Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro. |
| Q64125136 | Screening of an FDA-Approved Drug Library with a Two-Tier System Identifies an Entry Inhibitor of Severe Fever with Thrombocytopenia Syndrome Virus |
| Q90595084 | Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade |
| Q107011696 | Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir |
| Q104439722 | Simeprevir potently suppresses SARS-CoV-2 replication and synergizes with remdesivir |
| Q84315917 | Small-Molecule Antiviral β-d--Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance |
| Q107073747 | Snake venom phospholipases A2 possess a strong virucidal activity against SARS-CoV-2 in vitro and block the cell fusion mediated by spike glycoprotein interaction with the ACE2 receptor |
| Q100464752 | Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir |
| Q89568621 | Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein |
| Q90692545 | Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins |
| Q97692638 | Structural analysis of the SARS-CoV-2 methyltransferase complex involved in RNA cap creation bound to sinefungin |
| Q96339445 | Structural analysis of the putative SARS-CoV-2 primase complex |
| Q102378266 | Structure of nonstructural protein 1 from SARS-CoV-2 |
| Q89916071 | Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design |
| Q52653879 | Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element. |
| Q108784135 | Substrate Specificity of SARS-CoV-2 Nsp10-Nsp16 Methyltransferase |
| Q104502199 | Substrate specificity of SARS-CoV-2 nsp10-nsp16 methyltransferase |
| Q99608628 | Synthesis, Characterization and Computational Study on Potential Inhibitory Action of Novel Azo Imidazole Derivatives against COVID-19 Main Protease (Mpro: 6LU7) |
| Q57070745 | Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents |
| Q40094195 | TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections. |
| Q90744915 | Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19 |
| Q92800161 | The Curious Case of the Nidovirus Exoribonuclease: Its Role in RNA Synthesis and Replication Fidelity |
| Q94545219 | The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses |
| Q95603143 | The Host Cell ViroCheckpoint: Identification and Pharmacologic Targeting of Novel Mechanistic Determinants of Coronavirus-Mediated Hijacked Cell States |
| Q40410851 | The Middle East Respiratory Syndrome Coronavirus - A Continuing Risk to Global Health Security |
| Q38973838 | The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing. |
| Q101235429 | The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies |
| Q107455687 | The SARS‐unique domain (SUD) of SARS‐CoV and SARS‐CoV‐2 interacts with human Paip1 to enhance viral RNA translation |
| Q96123556 | The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast |
| Q57467989 | The celecoxib derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via down-regulation of the PI3K/Akt pathway and protects Zika virus-infected A129 mice: A host-targeting treatment strategy |
| Q90116485 | The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China |
| Q90243955 | The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options |
| Q107980878 | The human pandemic coronaviruses on the show: The spike glycoprotein as the main actor in the coronaviruses play |
| Q100430432 | The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies |
| Q90310442 | The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status |
| Q47173912 | The persistent prevalence and evolution of cross-family recombinant coronavirus GCCDC1 among a bat population: a two-year follow-up |
| Q30235533 | The role of laboratory diagnostics in emerging viral infections: the example of the Middle East respiratory syndrome epidemic |
| Q88045822 | Therapeutic options for the 2019 novel coronavirus (2019-nCoV) |
| Q90576406 | Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach |
| Q91897515 | Top Concerns of Tweeters During the COVID-19 Pandemic: Infoveillance Study |
| Q90744904 | Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective |
| Q38819802 | Understanding bat SARS-like coronaviruses for the preparation of future coronavirus outbreaks - Implications for coronavirus vaccine development |
| Q104452150 | Unexpected free fatty acid binding pocket in the cryo-EM structure of SARS-CoV-2 spike protein |
| Q90060949 | Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures |
| Q90637924 | Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target |
| Q97438274 | Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus |
| Q94547441 | Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature |
| Q99603877 | Viral pandemic preparedness: A pluripotent stem cell-based machine-learning platform for simulating SARS-CoV-2 infection to enable drug discovery and repurposing |
| Q91597822 | Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease |
| Q94680666 | What about the original antigenic sin of the humans versus SARS-CoV-2? |
| Q99419033 | What are the drugs having potential against COVID-19? |
| Q91954116 | Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms |
| Q27883663 | Zika Virus Infection in Dexamethasone-immunosuppressed Mice Demonstrating Disseminated Infection with Multi-organ Involvement Effectively Treated by Recombinant Type I Interferons |
| Q24261384 | Zika virus outbreak and the case for building effective and sustainable rapid diagnostics laboratory capacity globally |
| Q94589646 | [Conducting clinical studies during the epidemics of communicable diseases: perspectives of methodology and health economics] |
| Q111537568 | pH- and Calcium-Dependent Aromatic Network in the SARS-CoV-2 Envelope Protein |
Search more.